Speech-Language Pathologists in Stanton, KY Accepting Medicare

5 Speech-Language Pathologists found. Showing 1 - 5

Courtney Alexis Bowling, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 31 Derickson Ln, Stanton, KY 40380 Phone: 606-663-0435

Rebecka Laura Belcher, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 31 Derickson Ln, Stanton, KY 40380 Phone: 606-663-0435    Fax: 606-663-8040

Linda S Abner, CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 440 Washington St, Stanton, KY 40380 Phone: 606-663-5771    Fax: 606-663-5650

Charlene Nicole Skeens, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 31 Derickson Ln, Stanton, KY 40380 Phone: 606-663-0435

Speech Therapy Solutions, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 47 W Railroad St, Stanton, KY 40380 Phone: 606-663-8008    Fax: 606-663-0550

News Archive

Metric Applications Packages from ClearPoint Metrics

ClearPoint Metrics today announced a major expansion to its product offering with the delivery of four new Compliance oriented Metrics Application Packages (MAPS) and the integration of the ClearPoint Security Performance Manager (TM) and its compliance offering into a single solution - The ClearPoint Unified Security Performance and Compliance Manager.

Divorce linked with increased risk of future depression, but only for few people

Divorce is associated with an increased risk of future depressive episodes but only for those who already have a history of depression, according to a new study published in Clinical Psychological Science, a journal of the Association for Psychological Science.

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.

NanoScope awarded AGI Grant to re-sensitize photo-degenerated retinal areas with MCO

Millions of individuals affected by Retinitis Pigmentosa (RP) are visually impaired due to photo-degeneration of retina. The visual loss starts with the peripheral region progressing towards the center leading to tunnel vision. Currently, there is no cure to restore vision in these patients. The disease leads not only to physical impairment, but has a significant emotional and psychological impact on quality of life of patients as well as their family members.

Albert Einstein College of Medicine named 1 of 5 Nathan Shock Centers

Albert Einstein College of Medicine of Yeshiva University has been named one of the National Institutes of Health's (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging. The select group of five centers nationwide provides leadership in the pursuit of basic research into the biology of aging. Einstein's designation includes a $3.1 million, five-year grant from the NIH's National Institute on Aging.

Read more Medical News

› Verified 8 days ago